Testosterone Cypionate Pregnancy and Lactation Safety

Why Testosterone Cypionate Is Category X

Testosterone cypionate received the most restrictive FDA pregnancy classification available. Category X means that studies in animals or humans have demonstrated fetal abnormalities, and the risk to the fetus clearly outweighs any possible benefit to the patient. The FDA-approved prescribing information for testosterone cypionate states this explicitly in the Contraindications section.

The classification is not based on theoretical concern. Androgens are known teratogens. Exogenous testosterone crosses the placenta and reaches fetal circulation at pharmacologically active concentrations. In female fetuses, this exposure disrupts normal sexual differentiation. The external genitalia of 46,XX fetuses are sensitive to androgen signaling between gestational weeks 8 and 12, the period when the genital tubercle, labioscrotal folds, and urogenital sinus undergo differentiation. Testosterone exposure during this window produces dose-dependent masculinization that ranges from mild clitoromegaly to complete labioscrotal fusion with a penile urethra [1].

This is not a graded risk. Any clinically significant androgen exposure during the critical window can produce permanent anatomic changes that may require surgical correction.

Mechanism of Fetal Harm

Testosterone exerts its virilizing effects through direct activation of the androgen receptor in developing genital tissue. The drug also undergoes 5-alpha reduction to dihydrotestosterone (DHT), which binds the androgen receptor with roughly five-fold greater affinity than testosterone itself. DHT is the primary driver of external genital masculinization in both typical male development and in pathologic androgen exposure of female fetuses [2].

The biological pathway is well characterized. In a female fetus exposed to supraphysiologic androgens, the labioscrotal folds can fuse in the midline (mimicking scrotal development), the clitoris enlarges, and the urethral opening may migrate anteriorly. These changes are collectively termed virilization of the external genitalia, and they parallel the phenotype seen in congenital adrenal hyperplasia (CAH), a genetic condition that produces endogenous androgen excess in utero [3].

Internal reproductive structures (uterus, fallopian tubes, upper vagina) are typically preserved. These organs differentiate under the influence of Mullerian duct signaling rather than androgen receptor activation, so exogenous testosterone does not cause Mullerian regression in a 46,XX fetus.

Animal reproductive toxicology studies confirm the human clinical picture. Rat and rabbit studies documented dose-dependent virilization of female offspring, including anogenital distance increases (a standard marker of prenatal androgen exposure) and delayed vaginal opening [1].

Evidence From Human Case Reports and Cohort Data

No randomized controlled trials have intentionally exposed pregnant women to testosterone. The human evidence base comes from three sources: inadvertent exposures, case reports from transgender men who conceived while on testosterone, and data from women with endogenous hyperandrogenism.

A 2019 systematic review published in Obstetrics & Gynecology examined pregnancy outcomes in transgender men, some of whom had used testosterone prior to or during early pregnancy. Among pregnancies with first-trimester testosterone exposure, virilization of female neonates was reported in a subset of cases, though the exact incidence could not be calculated due to small sample sizes and inconsistent reporting [4].

Larger epidemiologic data come from the hyperandrogenism literature. Women with polycystic ovary syndrome (PCOS) have chronically elevated testosterone levels, though typically at concentrations well below those achieved with exogenous testosterone cypionate injections (which produce serum levels of 300 to 1,000+ ng/dL). Even the modest elevations seen in PCOS (typically 50 to 80 ng/dL) have been associated with increased anogenital distance in female offspring, a subclinical marker of androgen exposure, according to a prospective cohort study published in the Journal of Clinical Endocrinology & Metabolism [5].

The dose-response relationship matters. A standard testosterone cypionate injection of 100 to 200 mg weekly produces serum testosterone concentrations 5 to 15 times higher than the upper limit of the normal female range. Fetal exposure at these concentrations carries substantially greater risk than endogenous hyperandrogenism.

What Happens If Exposure Occurs Before Pregnancy Is Recognized

Some exposures are unintentional. A woman using low-dose testosterone for libido or a transgender man who has not discontinued testosterone may conceive before realizing they are pregnant. The clinical response depends on timing and duration.

If testosterone is discontinued before gestational week 8, the risk of genital virilization is lower because the critical differentiation window has not yet opened. Exposure limited to the first 6 to 7 weeks affects a period when the genital tubercle is still bipotential and has not begun sex-specific differentiation [3].

If exposure extends into weeks 8 through 12, referral to maternal-fetal medicine is appropriate. Detailed anatomic ultrasound at 18 to 22 weeks can assess fetal genital development, though mild virilization may not be detectable on imaging. Amniocentesis can confirm fetal karyotype if there is diagnostic uncertainty about fetal sex.

The Endocrine Society's 2017 clinical practice guideline on testosterone therapy in men with hypogonadism emphasizes that testosterone should be discontinued in any patient (or partner of a patient) planning conception. The guideline does not provide a protocol for accidental pregnancy exposure because the recommendation is absolute avoidance [6].

There is no antidote or reversal agent. Once androgen-mediated tissue changes have occurred in the fetus, they are permanent. The only intervention is cessation of the drug.

Testosterone Cypionate and Breastfeeding

Testosterone is contraindicated during lactation. The drug is lipophilic and transfers into breast milk. While the exact milk-to-plasma ratio for testosterone cypionate has not been quantified in formal pharmacokinetic studies, endogenous testosterone is present in human breast milk at measurable concentrations, and exogenous dosing would be expected to increase these levels substantially [7].

Neonates and infants have immature hepatic metabolism and may not clear exogenous androgens efficiently. Potential effects on the nursing infant include virilization, premature adrenarche, and disruption of the hypothalamic-pituitary-gonadal (HPG) axis during a critical developmental period. The National Library of Medicine's LactMed database lists testosterone as a drug to avoid during breastfeeding.

For women who require testosterone therapy postpartum (for example, for hypoactive sexual desire disorder), the decision to breastfeed versus treat must be individualized. There is no established "safe" waiting period after the last testosterone cypionate injection before initiating breastfeeding, though the drug's half-life of approximately 8 days suggests that 5 to 6 half-lives (40 to 48 days) would be needed to reach near-complete elimination.

Impact on Male Fertility and Conception Planning

Testosterone cypionate is not directly teratogenic through paternal exposure. A man using TRT does not pass exogenous testosterone to a fetus through seminal fluid at concentrations that would cause harm. The concern for male patients is different: exogenous testosterone suppresses the HPG axis, reducing intratesticular testosterone concentrations by 90% or more. This causes severe oligospermia or azoospermia in most men within 3 to 6 months of starting therapy [8].

The T-Trials, a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older with low testosterone, confirmed the hormonal efficacy of testosterone gel but did not assess fertility endpoints, as the study population was not seeking conception [9]. Fertility suppression data come primarily from male contraceptive studies. A WHO-sponsored trial of 200 mg testosterone enanthate weekly (pharmacokinetically similar to cypionate) found that 65% of men became azoospermic and 98% achieved severe oligospermia (<3 million sperm/mL) by 6 months [10].

Recovery is expected but not guaranteed. A meta-analysis in Fertility and Sterility reported that 67% of men recovered to baseline sperm concentration within 6 months of discontinuation, and 90% recovered within 12 months. A small percentage experienced prolonged or permanent impairment, particularly with longer duration of use [11].

For men planning conception, the American Urological Association's 2018 guideline on testosterone deficiency recommends discontinuing exogenous testosterone and substituting human chorionic gonadotropin (hCG) or selective estrogen receptor modulators (clomiphene or enclomiphene) to maintain androgen levels while preserving or restoring spermatogenesis [12].

Contraception Requirements for Women on Testosterone

Any woman of childbearing potential who is prescribed testosterone, whether for gender-affirming care, hypoactive sexual desire disorder, or off-label use, must use effective contraception throughout treatment. Testosterone itself is not a reliable contraceptive. While supraphysiologic androgen levels suppress ovulation in many women, breakthrough ovulation occurs unpredictably.

A 2014 survey of transgender men published in Obstetrics & Gynecology found that 5 of 41 respondents (12%) reported an unintended pregnancy while using testosterone [4]. Amenorrhea on testosterone does not equal anovulation. Barrier methods, IUDs, or progestin-only implants are all compatible with concurrent testosterone use.

"Testosterone is not birth control" is the single most important counseling point for prescribers. The American College of Obstetricians and Gynecologists (ACOG) has reinforced this in its guidance on health care for transgender and gender diverse individuals, recommending contraceptive counseling at every visit for transmasculine patients of reproductive age [13].

Preconception Planning Timeline

For women discontinuing testosterone before attempting pregnancy, a washout period is standard practice. Testosterone cypionate's terminal half-life of approximately 8 days means that serum levels will fall below the physiologic female range within 4 to 6 weeks of the last injection.

Ovulation may resume within 1 to 6 months of stopping testosterone, though individual variation is wide. Monitoring with serum estradiol, LH, and progesterone levels, combined with transvaginal ultrasound for follicular tracking, can confirm ovulatory recovery.

For male patients, preconception planning should begin 6 to 12 months before desired conception. Switching from testosterone cypionate to hCG (1,500 to 3 to 000 IU subcutaneously two to three times weekly) can maintain androgen levels at the low-normal range while stimulating intratesticular testosterone production sufficient for spermatogenesis. Semen analysis at 3-month intervals guides the timeline [12].

The minimum recommended semen analysis parameters for unassisted conception are those defined by the WHO Laboratory Manual, 6th edition (2021): total sperm count of 39 million or more per ejaculate, with 30% or more progressive motility [14].

Regulatory and Labeling Context

Every FDA-approved testosterone product, regardless of formulation (injectable, topical, buccal, nasal, subcutaneous pellet), carries the same Category X pregnancy classification. This includes brand names such as Depo-Testosterone (testosterone cypionate), Delatestryl (testosterone enanthate), AndroGel, Testim, Axiron, Natesto, and Jatenzo. The classification is based on the drug class mechanism, not on product-specific data.

The FDA's 2015 Pregnancy and Lactation Labeling Rule (PLLR) replaced the letter categories (A, B, C, D, X) with narrative subsections for newer drugs. Testosterone products approved before June 2015 retain the Category X label in their current prescribing information. Newer testosterone formulations use the PLLR format but contain equivalent language: "testosterone is contraindicated for use in pregnant or breastfeeding women" [1].

The European Medicines Agency (EMA) summary of product characteristics for testosterone-containing products mirrors the FDA position, classifying testosterone as contraindicated in pregnancy and lactation across all member states.

Patients who discover pregnancy while on testosterone cypionate should stop the medication immediately and contact their prescriber the same day.